Intravacc Signs Partnership with SynphaBase to Deliver End-to-End Conjugate Vaccine Development Services

Vaccine developers navigating the complexity of conjugate programs now have a single integrated pathway from synthetic oligosaccharide supply through GMP clinical manufacturing, following a strategic partnership announced by Intravacc and SynphaBase AG on 15 June 2026.

The collaboration pairs SynphaBase's glycochemistry and synthetic oligosaccharide capabilities with Intravacc's conjugation process development, scale-up, and GMP production infrastructure. Under the non-exclusive arrangement, both organisations will jointly offer services to third-party vaccine developers and, at Intravacc's discretion, to selected internal programs. SynphaBase may position Intravacc as a preferred CDMO for conjugation services; Intravacc may designate SynphaBase as a preferred oligosaccharide supplier within relevant programs.

For QA directors and regulatory leads, the structural relevance is in the supply-chain continuity the model provides. Sourcing synthetic oligosaccharides and conjugation development through separate, uncoordinated vendors introduces documentation gaps that can complicate process validation packages and delay IND submissions. A pre-aligned CDMO-CRO pairing, where regulatory support for oligosaccharide materials is built into the upstream relationship, reduces the coordination burden at the critical transition from development to clinical-scale manufacture.

SynphaBase's scope explicitly includes regulatory support for synthetic oligosaccharides across research, clinical development, and commercial supply stages, which positions the partnership to address one of the more friction-heavy segments of conjugate vaccine dossier preparation. Intravacc's existing cell-culture, bacterial, and conjugation platforms, combined with a stated track record in technology transfer, provide the downstream GMP framework that clients would otherwise need to source independently.

The agreement is non-exclusive, preserving client flexibility to engage alternative suppliers where program requirements dictate, a structural detail that plant heads evaluating vendor lock-in risk will note.

The measurable checkpoint for the partnership's utility will be the speed and regulatory completeness of the first shared client program to reach Phase I manufacturing.

Source: GlobeNewswire via Intravacc/SynphaBase press release, 15 June 2026.